SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Boehringer Ingelheim3,182 enrolled

Overview

This is a prospective, non-interventional, open-label, multi-centre study. It will provide additional safety information of Pradaxa in Korean patients with non-valvular AF in clinical settings.

Study Design: regulatory Post Marketed Surveillance study

Study Type

OBSERVATIONAL

Enrollment

3,182

Conditions

Atrial Fibrillation

Interventions

Pradaxa (Dabigatran etexilate mesilate)DRUG

110 mg or 150 mg b.i.d.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Age \>= 18 years at enrollment * Patients who have been started on Pradaxa in accordance with the approved label in Korea * Patients who have signed on the data release consent form Exclusion criteria: * Patients with previous exposure to Pradaxa * Clinically significant bleeding * Increased risk of bleeding due to following diseases; * Recent gastrointestinal ulceration * Recent intracranial or intracerebral bleeding history * Intraspinal or intracerebral vascular abnormalities * Recent brain, spinal or ophthalmic surgery * Recent brain or spinal injury * Known or suspected oesophageal varices * Arteriovenous malformations * Vascular aneurysms * Presence of malignant neoplasms at high risk of bleeding * Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under the circumstances of switching therapy to or from Pradaxa or when UFH is given at doses necessary to maintain an open central venous or arterial catheter * Severe renal impairment (CrCl \< 30mL/min) * Concomitant treatment with oral ketoconazole or dronedarone * Patients hypersensitive to dabigatran or dabigatran etexilate or to any ingredient in the formulation * Prosthetic heart valve replacement * No creatinine clearance collected within at least one year prior to enrollment * Current participation in other clinical trials

Locations (1)

Unnamed facility

Multiple Locations, South Korea

Outcomes

Primary Outcomes

Occurrence of Adverse Events(Including Unexpected Adverse Events, Serious Adverse Events, Drug-related Adverse Events, Adverse Events Leading to Discontinuation and Adverse Events by Intensity, Outcome of the Event, Causality)

Occurrence of adverse events(Including unexpected adverse events, serious adverse events, drug-related adverse events, adverse events leading to discontinuation and adverse events by intensity, outcome of the event, causality). Number analyzed presents the "Number of participants with Adverse events"

Time frame: up to 26 weeks

Secondary Outcomes

Percentage of Participants With Stroke

Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction.

Time frame: up to 26 weeks

Percentage of Participants With Systemic Embolism

Systemic embolism was defined as an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and was to be documented by angiography, surgery, scintigraphy or autopsy.

Time frame: up to 26 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.